Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...
Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...
Panelists discuss their excitement about the evolution of heart failure as a distinct specialty with multiple effective therapeutic options, the convergence of previously siloed medical disciplines ...
Dialysis may improve outcomes in patients suffering from treatment-resistant congestive heart failure (CHF) accompanied by severe renal insufficiency, new findings suggest. Trijntje T. Cnossen, MD, ...
Mölndal, Sweden, 9 March 2004 – Data presented today at the American College of Cardiology (ACC) annual meeting add weight to the evidence shown in the original publications from the CHARM* Programme ...
The researchers of a recent British Medical Journal paper reviewed heart failure diagnosis and management data. Heart failure has led to considerable health and financial burdens globally, especially ...
LISBON, Portugal—The results are mixed when it comes to the application of guideline-directed medical therapy (GDMT) for the treatment of heart failure (HF), two new studies have found, with one ...
Adults who have heart failure with a left ventricular ejection fraction of 40% or more face a high risk of hospitalization for heart failure and cardiovascular death. People who have heart failure ...
When the heart can no longer pump blood efficiently throughout the body, kidney function issues are among the first complications to develop. Congestive heart failure (CHF), a condition that reflects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results